atezolizumab,durvalumab
roche,astrazeneca
['durvalumab', 'bladder', 'atezo']
it looks like pcr may not be discriminatory for predicting outcome in neoadjuvant bladder cancer. landmark dfs in this chemo/durvalumab and previous atezo trials look promising. outcome of the randomised trials such niagra are awaited #asco22 
Interested in Urology Cancers, biomarkers and drug development.